EUVIMEDEUVIMED entdecken
Crossref

Dapagliflozin and chiglitazar combination enhanced myocardial energy metabolism in high‐fat diet‐fed mice

Jieying Liu, Jing Zhou, Shunhua Li, Ziyan Xie iD, Mengyu He, Jing Liu, Xuemei Ma, Miao Yu iD, Dongmei Wang iD, Xinhua Xiao iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Jieying Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Diabetes Research Center of Chinese Academy of Medical Sc…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Energy Metabolism, Myocardium. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Beijing Municipal Science & Technology Commission, National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Oral antidiabetic drugs dapagliflozin and chiglitazar have shown potential effects in improving myocardial metabolism. This study aimed to investigate their combined impacts on cardiac energy metabolism in high‐fat diet (HFD)‐induced obesity mice.

Methods

Male C57BL/6N mice were randomized into seven groups: (1) normal chow control, (2) high‐fat diet (HFD) control, (3) dapagliflozin monotherapy, (4) low dose of chiglitazar monotherapy, (5) high dose of chiglitazar monotherapy and (6, 7) combination therapy groups with dapagliflozin and varying doses of chiglitazar. Myocardial tissues were subjected to targeted metabolomic analysis for free fatty acids (FFAs) species and key intermediates in central carbon metabolism pathways.

Results

The combination therapy significantly improved overall metabolic phenotypes and reduced cardiac lipid droplet size in HFD mice. FFAs profile analysis showed an increased proportion of unsaturated FFAs and a decreased proportion of saturated FFAs. The central carbon metabolism analysis demonstrated alterations in energy metabolic pathways, including glycolysis, purine and pyrimidine metabolism, amino acid metabolism, and the tricarboxylic acid (TCA) cycle. Combined analysis of FFAs and central carbon showed that the TCA cycle was accelerated and ATP production was increased compared with monotherapy. Decreased expression of acetyl‐CoA carboxylase 1, increased expression of carnitine palmitoyltransferase 1, as well as elevated levels of citrate synthase and isocitrate dehydrogenase, were validated by Western blot.

Conclusions

The combination of dapagliflozin and chiglitazar improved cardiac fatty acid and central carbon metabolism, among which acceleration of metabolic flux through the TCA cycle, increased ATP production, and upregulation of key enzyme expression might represent the key beneficial mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesEnergy MetabolismMyocardiumHypoglycemic AgentsObesityAnimalsDiet, High-FatMaleMice, Inbred C57BLMiceDrug Therapy, CombinationSodium-Glucose Transporter 2 InhibitorsHeart

Stichwörter der Autor:innen

chiglitazarcombination effectdapagliflozinenergy metabolismmyocardial metabolism

Substanzen

Benzhydryl CompoundsGlucosidesdapagliflozinHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Diabetes Research Center of Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Peking Union Medical Co…
  • Center for Biomarker Discovery and Validation, National Infrastructures for Translational Medicine (PUMCH), Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Bei…
  • Department of Endocrinology, Genetics, Metabolism, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

ORCID-Profile: Ziyan Xie, Miao Yu, Dongmei Wang, Xinhua Xiao

Förderung

  • Beijing Municipal Science & Technology Commission
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • National High Level Hospital Clinical Research Funding
  • CAMS Innovation Fund for Medical Sciences
  • Fundamental Research Funds for the Central Universities
  • Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park

Zitieren

APA

Liu, J., Zhou, J., Li, S., Xie, Z., He, M., Liu, J., Ma, X., Yu, M., Wang, D., & Xiao, X. (2026). Dapagliflozin and chiglitazar combination enhanced myocardial energy metabolism in high‐fat diet‐fed mice. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70327

Vancouver

Liu J, Zhou J, Li S, Xie Z, He M, Liu J, et al. Dapagliflozin and chiglitazar combination enhanced myocardial energy metabolism in high‐fat diet‐fed mice. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70327

BibTeX
@article{Liu2026,
  author = {Liu, Jieying and Zhou, Jing and Li, Shunhua and Xie, Ziyan and He, Mengyu and Liu, Jing and Ma, Xuemei and Yu, Miao and Wang, Dongmei and Xiao, Xinhua},
  title = {Dapagliflozin and chiglitazar combination enhanced myocardial energy metabolism in high‐fat diet‐fed mice},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70327}
}
Kostenlos starten →